Literature DB >> 10342079

Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.

E A Schaff1, S H Eisinger, L S Stadalius, P Franks, B Z Gore, S Poppema.   

Abstract

The objectives of this study were to determine the effectiveness, side effects, and acceptability of one-third the standard 600 mg dose of mifepristone (200 mg) to induce abortion. A prospective trial at seven sites enrolled women > or = 18 years, up to 8 weeks pregnant, and wanting an abortion. The women received 200 mg mifepristone orally, self-administered 800 micrograms misoprostol vaginally at home 48 h later, and returned 1-4 days later for ultrasound evaluation. Surgical intervention was indicated for continuing pregnancy, excessive bleeding, persistent products of conception 5 weeks later, or other serious medical conditions. Of the 933 subjects, 906 (97%) had complete medical abortions, 22 had surgical intervention, two were protocol failures, and three were lost to follow up. Of the 746 subjects who had no or minimal bleeding before misoprostol, 80% bled within 4 h and 98% within 24 h of using misoprostol. By day 7, 95% of women had a complete abortion. Side effects were aceptable in 85% of subjects, and 94% found the procedure acceptable. Low-dose mifepristone followed by vaginal misoprostol was highly effective as an abortifacient.

Entities:  

Keywords:  Abortifacient Agents; Abortion, Drug Induced; Abortion, Induced; Americas; Biology; Clinical Research; Clinical Trials; Developed Countries; Endocrine System; Family Planning; Fertility Control, Postconception; Hormone Antagonists; Hormones; Misoprostol; North America; Northern America; Physiology; Prostaglandins; Prostaglandins, Synthetic; Research Methodology; Research Report; Ru-486--administraction and dosage; Ru-486--side effects; United States

Mesh:

Substances:

Year:  1999        PMID: 10342079     DOI: 10.1016/s0010-7824(98)00150-4

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

Review 1.  Medical liability insurance as a barrier to the provision of abortion services in family medicine.

Authors:  Christine E Dehlendorf; Kevin Grumbach
Journal:  Am J Public Health       Date:  2008-08-13       Impact factor: 9.308

2.  Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.

Authors:  Mary Gatter; Kelly Cleland; Deborah L Nucatola
Journal:  Contraception       Date:  2015-01-13       Impact factor: 3.375

3.  Early abortion in family medicine: clinical outcomes.

Authors:  Ian M Bennett; Margaret Baylson; Karin Kalkstein; Ginger Gillespie; Scarlett L Bellamy; Joan Fleischman
Journal:  Ann Fam Med       Date:  2009 Nov-Dec       Impact factor: 5.166

Review 4.  Medication to Manage Abortion and Miscarriage.

Authors:  Jessica Beaman; Christine Prifti; Eleanor Bimla Schwarz; Mindy Sobota
Journal:  J Gen Intern Med       Date:  2020-05-14       Impact factor: 5.128

5.  Silent uterine rupture with the use of misoprostol for second trimester termination of pregnancy : a case report.

Authors:  Martin Cuellar Torriente
Journal:  Obstet Gynecol Int       Date:  2011-04-19

6.  Comparing the World Health Organization-versus China-recommended protocol for first-trimester medical abortion: a retrospective analysis.

Authors:  Thoai D Ngo; Min Hae Park; Yuanhong Xiao
Journal:  Int J Womens Health       Date:  2012-03-26

7.  Trends in medication abortion and the role of low-volume and nonmetropolitan mifepristone purchasers: 2008-2011 and 2014-2017.

Authors:  Rachel K Jones
Journal:  Contracept X       Date:  2020-10-13

8.  The effectiveness of using misoprostol with and without letrozole for successful medical abortion: A randomized placebo-controlled clinical trial.

Authors:  Elham Naghshineh; Zahra Allame; Faezah Farhat
Journal:  J Res Med Sci       Date:  2015-06       Impact factor: 1.852

9.  Development of A Machine Learning Algorithm to Classify Drugs Of Unknown Fetal Effect.

Authors:  Mary Regina Boland; Fernanda Polubriaginof; Nicholas P Tatonetti
Journal:  Sci Rep       Date:  2017-10-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.